Leonid Timashev
RBC Capital Markets, Research Division

[ Thank you ] for joining us for our next session at the RBC Healthcare Conference. Here, we've got Nuvation, represented by David, their CEO; and Philippe, their CFO. Thanks for being here.

David Hung
Founder, President, CEO & Chairman

Thanks for having us.

Leonid Timashev
RBC Capital Markets, Research Division

So, there's a lot going on at the company, but I figured maybe we'd start on the commercial side of the business first. So, first you achieved $18.5 million in first quarter revenues, about 200 new patient starts, and you talked about revenue stacking as a goal. So I guess, what are your expectations for how you're going to be driving growth for the balance of the year?

David Hung
Founder, President, CEO & Chairman

So if you look at, we've been out for 3 quarters and if you look at new patient starts in each quarter, it's been about 200 new patient starts per quarter, which is more than the combined new patient starts of Augtyro and entrectinib combined. So it's a good start. But the number that we find most important is the percentage of first-line patients because the duration of response of first-line patients is over 4 years, which -- so every patient who starts in the first-line setting would be expected to generate revenue for 4 years plus, about 4.2 years.

If you look at third-line patients or fourth-line patients, they're on drug for a few months. And so when you look